NZ509129A - Vitamin E and esters thereof for use in the topical treatment of mucosal pathologies - Google Patents
Vitamin E and esters thereof for use in the topical treatment of mucosal pathologiesInfo
- Publication number
- NZ509129A NZ509129A NZ509129A NZ50912999A NZ509129A NZ 509129 A NZ509129 A NZ 509129A NZ 509129 A NZ509129 A NZ 509129A NZ 50912999 A NZ50912999 A NZ 50912999A NZ 509129 A NZ509129 A NZ 509129A
- Authority
- NZ
- New Zealand
- Prior art keywords
- vitamin
- compound
- medicament
- preparation
- acetate
- Prior art date
Links
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229930003427 Vitamin E Natural products 0.000 title claims abstract description 31
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229940046009 vitamin E Drugs 0.000 title claims abstract description 31
- 239000011709 vitamin E Substances 0.000 title claims abstract description 31
- 235000019165 vitamin E Nutrition 0.000 title claims abstract description 31
- 150000002148 esters Chemical class 0.000 title claims abstract description 24
- 230000000699 topical effect Effects 0.000 title claims description 42
- 230000007170 pathology Effects 0.000 title claims description 22
- 208000001688 Herpes Genitalis Diseases 0.000 claims abstract description 10
- 201000004946 genital herpes Diseases 0.000 claims abstract description 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 10
- 230000001857 anti-mycotic effect Effects 0.000 claims abstract description 8
- 239000002543 antimycotic Substances 0.000 claims abstract description 8
- 239000005556 hormone Substances 0.000 claims abstract description 8
- 229940088597 hormone Drugs 0.000 claims abstract description 8
- 230000003637 steroidlike Effects 0.000 claims abstract description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 7
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims abstract description 7
- 229940042585 tocopherol acetate Drugs 0.000 claims description 71
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 70
- 210000004877 mucosa Anatomy 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 27
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 21
- 206010023332 keratitis Diseases 0.000 claims description 16
- 208000003265 stomatitis Diseases 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 14
- 208000003251 Pruritus Diseases 0.000 claims description 13
- 208000025865 Ulcer Diseases 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 13
- 208000001780 epistaxis Diseases 0.000 claims description 13
- 230000007803 itching Effects 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 12
- 230000003902 lesion Effects 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 9
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 201000003079 ectropion Diseases 0.000 claims description 8
- 150000001735 carboxylic acids Chemical class 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 210000002200 mouth mucosa Anatomy 0.000 claims description 6
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 208000004746 Atrophic Vaginitis Diseases 0.000 claims description 4
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 208000005232 Glossitis Diseases 0.000 claims description 2
- 230000001133 acceleration Effects 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 3
- 235000020778 linoleic acid Nutrition 0.000 claims 3
- 239000001384 succinic acid Substances 0.000 claims 3
- 208000035824 paresthesia Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- -1 antibiotic Substances 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 description 16
- 210000001508 eye Anatomy 0.000 description 16
- 230000008901 benefit Effects 0.000 description 15
- 230000009467 reduction Effects 0.000 description 14
- 230000001575 pathological effect Effects 0.000 description 12
- 230000008034 disappearance Effects 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 210000000214 mouth Anatomy 0.000 description 9
- 230000000306 recurrent effect Effects 0.000 description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 229930003799 tocopherol Natural products 0.000 description 8
- 229960001295 tocopherol Drugs 0.000 description 8
- 239000011732 tocopherol Substances 0.000 description 8
- 235000010384 tocopherol Nutrition 0.000 description 8
- 208000002003 vulvitis Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 210000002850 nasal mucosa Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010036774 Proctitis Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000842539 Rhagades Species 0.000 description 5
- 206010040849 Skin fissures Diseases 0.000 description 5
- 206010046996 Varicose vein Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000003560 epithelium corneal Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000036269 ulceration Effects 0.000 description 5
- 208000027185 varicose disease Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000034347 Faecal incontinence Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 201000007717 corneal ulcer Diseases 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 230000001932 seasonal effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 230000001720 vestibular Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 206010068172 Anal pruritus Diseases 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 3
- 206010067152 Oral herpes Diseases 0.000 description 3
- 208000009544 Pruritus Ani Diseases 0.000 description 3
- 206010064996 Ulcerative keratitis Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000013043 chemical agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 230000000642 iatrogenic effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 201000010727 rectal prolapse Diseases 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010028781 Nasal vestibulitis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- 206010044604 Trichiasis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 206010005159 blepharospasm Diseases 0.000 description 2
- 230000000744 blepharospasm Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002573 colposcopy Methods 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- VURKRJGMSKJIQX-UHFFFAOYSA-N xanthopterin Chemical compound N1C(=O)C=NC2=C1C(=O)N=C(N)N2 VURKRJGMSKJIQX-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007877 Cell-mediated immune deficiency Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 208000006819 Denture Stomatitis Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 108010019393 Fibrin Foam Proteins 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 206010017012 Foreign body in eye Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000006219 Herpangina Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 241001123008 Leukoma Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 206010028780 Nasal ulcer Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010061549 Sensation of foreign body Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000003827 Vulvar Vestibulitis Diseases 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004045 bowman membrane Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 230000009992 cAMP activation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 201000009819 exposure keratitis Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000729 hypotrophic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000783 smooth endoplasmic reticulum Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98MI001586A ITMI981586A1 (it) | 1998-07-10 | 1998-07-10 | Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose |
| PCT/IB1999/001238 WO2000002554A1 (en) | 1998-07-10 | 1999-07-05 | Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ509129A true NZ509129A (en) | 2003-10-31 |
Family
ID=11380415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ509129A NZ509129A (en) | 1998-07-10 | 1999-07-05 | Vitamin E and esters thereof for use in the topical treatment of mucosal pathologies |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1094807B1 (enExample) |
| JP (1) | JP2002520281A (enExample) |
| CN (1) | CN1135975C (enExample) |
| AT (1) | ATE238051T1 (enExample) |
| AU (1) | AU762860B2 (enExample) |
| BR (1) | BR9911945A (enExample) |
| CA (1) | CA2336990A1 (enExample) |
| CZ (1) | CZ301019B6 (enExample) |
| DE (1) | DE69907193T2 (enExample) |
| DK (1) | DK1094807T3 (enExample) |
| ES (1) | ES2196813T3 (enExample) |
| HU (1) | HU228921B1 (enExample) |
| IL (1) | IL140759A0 (enExample) |
| IT (1) | ITMI981586A1 (enExample) |
| NO (1) | NO20006719L (enExample) |
| NZ (1) | NZ509129A (enExample) |
| PL (1) | PL345500A1 (enExample) |
| PT (1) | PT1094807E (enExample) |
| RU (2) | RU2221561C2 (enExample) |
| SK (1) | SK284464B6 (enExample) |
| TR (2) | TR200100014T2 (enExample) |
| WO (1) | WO2000002554A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
| FR2819186A1 (fr) * | 2001-01-10 | 2002-07-12 | L M D | Cystine-voie orale-syndrome de l'oeil sec |
| FR2825088A1 (fr) * | 2001-05-25 | 2002-11-29 | Derma Dev | Nouveaux esters de tocopherol, leurs procedes d'obtention et leurs utilisations |
| US7485666B2 (en) * | 2004-06-17 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
| US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| RU2428973C2 (ru) * | 2005-03-03 | 2011-09-20 | Вайтал Хэлф Сайнсис Пти Лтд | Составы, обладающие липидопонижающими свойствами |
| JP5731980B2 (ja) * | 2008-10-09 | 2015-06-10 | ラムズコア， インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
| IT1394063B1 (it) * | 2009-05-11 | 2012-05-25 | Giuliani Spa | Composizione per uso oftalmico adatta al trattamento degli stati infiammatori dell'occhio e della sindrome dell'occhio secco |
| RU2540481C2 (ru) * | 2009-07-27 | 2015-02-10 | Сальваторе Троизи | Офтальмологический раствор для защиты внутренних структур глазного яблока от уф-а лучей или для лечения кератоконуса методом трансэпителиального кросс-линкинга |
| WO2013049749A2 (en) | 2011-09-29 | 2013-04-04 | Plx Pharma Inc. | pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME |
| WO2013185024A1 (en) * | 2012-06-08 | 2013-12-12 | The Ohio State University | Treating burn and scar injury using tocotrienol |
| DE202014106007U1 (de) * | 2014-07-22 | 2015-07-23 | Bio.Lo.Ga. S.R.L. | Zusammensetzung zur Verwendung in der Vorbeugung und Behandlung allergischer Rhinitis |
| LT3209294T (lt) * | 2014-10-22 | 2019-10-25 | Bio Lo Ga Srl | Farmacinė kompozicija, skirta panaudoti nosies gleivinės trofizmo padidinimui |
| JP2018507895A (ja) * | 2015-03-18 | 2018-03-22 | バイオヌークス スイス エスエー | ヘルペスを処置するための方法において使用するためのジヒドロケルセチンを含む組成物 |
| JP2017119669A (ja) * | 2015-10-15 | 2017-07-06 | ロート製薬株式会社 | 異物感改善用眼科組成物 |
| WO2020053783A1 (en) * | 2018-09-12 | 2020-03-19 | Neilos S.r.l. | A composition for use in the prevention and/or treatment of epistaxis |
| IT202000003620A1 (it) | 2020-02-21 | 2021-08-21 | Hulka S R L | Uso di una formulazione per applicazione topica per il mantenimento dell’omeostasi vaginale |
| KR20220158031A (ko) | 2020-03-26 | 2022-11-29 | 피엘엑스 옵코 인코포레이티드 | pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59216812A (ja) * | 1983-05-26 | 1984-12-06 | Dowa Yakushiyou Kk | 頭髪育毛料 |
| JP2776837B2 (ja) * | 1988-08-11 | 1998-07-16 | 日本レダリー株式会社 | 消化性潰瘍治療剤 |
| US5032384A (en) * | 1989-01-27 | 1991-07-16 | Block Drug Company, Inc. | Compositions and method for the treatment of disease |
| SU1628281A3 (ru) * | 1989-03-30 | 1994-02-28 | Научно-производственная фирма "Флори" | Ранозаживляющее средство |
| IT1249711B (it) * | 1991-09-30 | 1995-03-09 | Boniscontro E Gazzone S R L | Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici,indicate nella terapia dei tessuti superficiali. |
| JP2811036B2 (ja) * | 1992-05-26 | 1998-10-15 | 参天製薬株式会社 | ビタミンｅ点眼剤 |
| JP3551977B2 (ja) * | 1993-04-08 | 2004-08-11 | ライオン株式会社 | 安定なビタミンａ類及びビタミンｅ類可溶化点眼剤 |
| CN1039087C (zh) * | 1993-12-29 | 1998-07-15 | 昆明宏达实业有限总公司 | 妇科病治疗保健外用药物 |
| RU2125887C1 (ru) * | 1995-08-25 | 1999-02-10 | Владивостокский государственный медицинский университет | Способ приготовления липосомального интерферона |
| IT1282778B1 (it) * | 1996-05-31 | 1998-03-31 | Giorgio Panin | Vitamina "e" acetato quale prodotto per applicazione topica |
| JPH10109934A (ja) * | 1996-10-04 | 1998-04-28 | Sekisui Chem Co Ltd | 炎症性眼疾患用剤 |
| JPH10231243A (ja) * | 1997-02-20 | 1998-09-02 | Sekisui Chem Co Ltd | 粘膜炎症外用薬 |
-
1998
- 1998-07-10 IT IT98MI001586A patent/ITMI981586A1/it unknown
-
1999
- 1999-07-05 RU RU2001101122/15A patent/RU2221561C2/ru active
- 1999-07-05 TR TR2001/00014T patent/TR200100014T2/xx unknown
- 1999-07-05 DE DE69907193T patent/DE69907193T2/de not_active Expired - Lifetime
- 1999-07-05 CA CA002336990A patent/CA2336990A1/en not_active Abandoned
- 1999-07-05 DK DK99926687T patent/DK1094807T3/da active
- 1999-07-05 BR BR9911945-5A patent/BR9911945A/pt not_active Application Discontinuation
- 1999-07-05 TR TR2001/03710T patent/TR200103710T2/xx unknown
- 1999-07-05 NZ NZ509129A patent/NZ509129A/en not_active IP Right Cessation
- 1999-07-05 AU AU43858/99A patent/AU762860B2/en not_active Expired
- 1999-07-05 WO PCT/IB1999/001238 patent/WO2000002554A1/en not_active Ceased
- 1999-07-05 JP JP2000558814A patent/JP2002520281A/ja active Pending
- 1999-07-05 CN CNB998084328A patent/CN1135975C/zh not_active Expired - Lifetime
- 1999-07-05 AT AT99926687T patent/ATE238051T1/de active
- 1999-07-05 HU HU0102781A patent/HU228921B1/hu unknown
- 1999-07-05 PT PT99926687T patent/PT1094807E/pt unknown
- 1999-07-05 EP EP99926687A patent/EP1094807B1/en not_active Expired - Lifetime
- 1999-07-05 CZ CZ20010036A patent/CZ301019B6/cs unknown
- 1999-07-05 IL IL14075999A patent/IL140759A0/xx unknown
- 1999-07-05 SK SK35-2001A patent/SK284464B6/sk unknown
- 1999-07-05 ES ES99926687T patent/ES2196813T3/es not_active Expired - Lifetime
- 1999-07-05 PL PL99345500A patent/PL345500A1/xx not_active Application Discontinuation
-
2000
- 2000-12-29 NO NO20006719A patent/NO20006719L/no not_active Application Discontinuation
-
2003
- 2003-09-11 RU RU2003128023/15A patent/RU2003128023A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1094807B1 (en) | 2003-04-23 |
| ITMI981586A1 (it) | 2000-01-10 |
| ATE238051T1 (de) | 2003-05-15 |
| PL345500A1 (en) | 2001-12-17 |
| SK352001A3 (en) | 2001-06-11 |
| HUP0102781A2 (hu) | 2001-12-28 |
| PT1094807E (pt) | 2003-08-29 |
| TR200100014T2 (tr) | 2001-06-21 |
| RU2003128023A (ru) | 2005-04-10 |
| DK1094807T3 (da) | 2003-08-11 |
| JP2002520281A (ja) | 2002-07-09 |
| SK284464B6 (sk) | 2005-04-01 |
| WO2000002554A1 (en) | 2000-01-20 |
| AU4385899A (en) | 2000-02-01 |
| EP1094807A1 (en) | 2001-05-02 |
| CN1308531A (zh) | 2001-08-15 |
| BR9911945A (pt) | 2001-03-27 |
| IL140759A0 (en) | 2002-02-10 |
| DE69907193D1 (de) | 2003-05-28 |
| AU762860B2 (en) | 2003-07-10 |
| ES2196813T3 (es) | 2003-12-16 |
| DE69907193T2 (de) | 2004-04-08 |
| CZ200136A3 (cs) | 2001-08-15 |
| CN1135975C (zh) | 2004-01-28 |
| NO20006719D0 (no) | 2000-12-29 |
| CZ301019B6 (cs) | 2009-10-14 |
| HU228921B1 (en) | 2013-06-28 |
| ITMI981586A0 (it) | 1998-07-10 |
| RU2221561C2 (ru) | 2004-01-20 |
| NO20006719L (no) | 2001-02-16 |
| TR200103710T2 (tr) | 2002-06-21 |
| CA2336990A1 (en) | 2000-01-20 |
| HUP0102781A3 (en) | 2002-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU762860B2 (en) | Vitamin E and esters thereof for use in the topical treatment of mucosal pathologies | |
| JP5118633B2 (ja) | 医療用デバイスおよび医薬製剤において有用な粘膜付着性キシログルカン含有製剤 | |
| US20230013824A1 (en) | Compositions for the treatment of hyperkeratosis disorders | |
| DK2343038T3 (en) | Dermatological compositions containing a combination of peroxidized lipids and zinc and their use, especially for the treatment of herpes | |
| US10980762B2 (en) | Wound healing composition | |
| JPS6365050B2 (enExample) | ||
| CN112770765A (zh) | 用于预防和/或治疗泌尿生殖器粘膜的组合物 | |
| CN105395899A (zh) | 天麻的外用剂型 | |
| EP4106783B1 (en) | Composition for the treatment of skin and mucous membrane diseases | |
| MXPA01000368A (en) | Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies | |
| US8492443B2 (en) | Treatment for herpes simplex virus and other infectious diseases | |
| US20260102359A1 (en) | Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation | |
| WO2025224482A1 (es) | Composición a base de acmella oppositifolia y de matricaria chamomilla | |
| US20250064881A1 (en) | Topical composition and applicator therefor for relieving chalazion | |
| CA3268830A1 (en) | Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation | |
| Serbelloni et al. | Pruritus Ani | |
| Johnston et al. | Common rashes in children: 1 | |
| CA2591352A1 (en) | Treatment for herpes simplex virus and other infectious diseases | |
| HK40004310A (en) | Compositions for the treatment of hyperkeratosis disorders | |
| US20160199326A1 (en) | Use of trifluoroacetic acid as keratolytic agent to treat hyperkeratotic skin lesions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |